/
PGEN
$6.49-$0.36 (-5.26%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.5B
358M shares
52-week range
$1.80 – $7.32
85% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$0.64
Precigen, Inc. Common Stock
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
www.precigen.com- Employees
- 47
- IPO / List date
- Aug 8, 2013
- HQ
- GERMANTOWN, MD
Held by traders on TradeandTell
No one on the platform currently holds PGEN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 287,403 | $408.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PGEN yet.
